Stock IPCI.H INTELLIPHARMACEUTICS INTERNATIONAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Intellipharmaceutics International Inc.

Equities

IPCI.H

CA4581733090

Pharmaceuticals

Delayed Toronto S.E.
Other stock markets
 12:00:00 2024-03-21 pm EDT 		5-day change 1st Jan Change
0.08 CAD -.--% Intraday chart for Intellipharmaceutics International Inc. -11.11% +6.67%
Jan. 03 IntelliPharmaCeutics International Receives Conditional Approval For TSXV Listing MT
2023 Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023 CI

Business Summary

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.

Number of employees: 11

Sales per Business

CAD in Million2021Weight2022Weight Delta
Licensing
45.2 %
- - 0 45.2 % -
Up-front Fees
29.0 %
- - 0 29.0 % -
Other Services
25.8 %
- - 0 25.8 % -

Sales per region

CAD in Million2021Weight2022Weight Delta
United States
45.2 %
-- 0 45.2 % -
Canada
29.0 %
0 nan % 0 29.0 % -
Other
25.8 %
-- 0 25.8 % -

Managers

Managers TitleAgeSince
Amina Odidi FOU
 Founder - 97-12-31
Isa Odidi CEO
 Chief Executive Officer - 97-12-31
Fazayill Shaideen AUD
 Comptroller/Controller/Auditor - 07-03-31
Christian Akyempon PRN
 Corporate Officer/Principal - 14-01-31
Patrick Yat PRN
 Corporate Officer/Principal - 91-12-31

Members of the board

Members of the board TitleAgeSince
Norman Betts BRD
 Director/Board Member 68 19-01-21
Isa Odidi CEO
 Chief Executive Officer - 97-12-31
Amina Odidi FOU
 Founder - 97-12-31
Bahadur Madhani BRD
 Director/Board Member - 06-02-28
Shawn Graham BRD
 Director/Board Member - 18-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,092,665 32,511,067 ( 98.24 %) 0 98.24 %

Shareholders

NameEquities%Valuation
Armistice Capital LLC
10.49 %
3,672,877 10.49 % 260 774 $
Odidi Holdings, Inc.
1.652 %
578,131 1.652 % 41 047 $
Patrick Yat
0.007762 %
2,717 0.007762 % 193 $
Bahadur Madhani
0.002143 %
750 0.002143 % 53 $
ANIMA Sgr SpA
0.000043 %
15 0.000043 % 1 $
UBS AG (Investment Management)
0.000040 %
14 0.000040 % 1 $
Value Management & Research AG (Invt Mgmt)
0.000029 %
10 0.000029 % 1 $
Deans Knight Capital Management Ltd.
0.000020 %
7 0.000020 % 0 $
Fiera Holdings, Inc.
0.000006 %
2 0.000006 % 0 $
Manulife Investment Management Ltd.
0.000003 %
1 0.000003 % 0 $

Holdings

NameEquities%Valuation
GROWLIFE, INC.
10.84%
 3,662,761 10.84% 7,326 $

Company contact information

Intellipharmaceutics International, Inc.

30 Worcester Road

M9W 5X2, Toronto

+416 798 3001

http://www.intellipharmaceutics.com
address Intellipharmaceutics International Inc.(IPCI.H)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
INTELLIPHARMACEUTICS INTERNATIONAL INC. Stock Intellipharmaceutics International Inc.
+6.67% 1.93M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IPCI.H Stock
  4. Company Intellipharmaceutics International Inc.